Hormônio de crescimento em crianças e adolescentes com fbrose cística

Abstract

The recombinant human growth hormone (rhGH) can improve weight gain, physical growth, clinical and lung in cystic fbrosis (CF). However, the routine use, although promising, is not established in the literature. The objective of this study was to assess the benefts of rhGH in children and adolescents with C F. We conducted a systematic review in the database PubMed, Lilacs, SciELO and Cochrane, in the period 2000-2010, using the keywords: "cystic fbrosis", "growth hormone", "children" and "adolescents". We found 77 articles and included 11 randomized controlled trials, with 290 children and adolescents with C F. The short-term use (1-24 months) of rhGH improved the height, weight, growth rate, bone mineral content and components of pulmonary function. Adverse effects, like diabetes, were not observed in the studies. The short-term use of rhGH improved growth and body composition in patients with C F.